Phesgo Market Report 2026

Phesgo Market Overview

• The Phesgo market growth in the historic period has been driven by increasing diagnosis of her2-positive breast cancer, advancements in monoclonal antibody development • Market expansion is supported by expansion of home-based oncology treatment models, rising investments in combination biologic therapies • Growth Driver: Surge In Incidences Of Breast Cancer Driving Market Growth Due To Increased Need For Targeted Oncology Therapies • Market Trend: Innovative Monoclonal Antibody Combination Therapy Enhancing Oncology Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Phesgo Market?

Phesgo refers to a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase for subcutaneous injection. It is used for treating HER2-positive breast cancer in both early and metastatic stages, often in combination with chemotherapy. The main indications of phesgo are early breast cancer and metastatic breast cancer. Early breast cancer, diagnosed at stages 0, I, or II, is treated with Phesgo, a combination of pertuzumab and trastuzumab, to reduce the risk of recurrence in HER2-positive cases. It is available in various formulations, such as subcutaneous injection and intravenous infusion. It is distributed through various channels such as direct sales, online pharmacies, and wholesale distributors and is used by various end users, including hospitals, oncology clinics, and home healthcare.

What Is The Phesgo Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of home-based oncology treatment models, rising investments in combination biologic therapies, increasing adoption of subcutaneous drug delivery, advancements in formulation stability technologies, growing demand for efficient cancer treatment protocols. Major trends in the forecast period include increasing adoption of fixed-dose combination therapies, rising preference for subcutaneous oncology treatments, expansion of her2-positive breast cancer therapies, growing focus on patient convenience and compliance, enhanced biologic formulation technologies.

Global Phesgo Market Segmentation

1) By Indication: Early Breast Cancer, Metastatic Breast Cancer 2) By Formulation: Subcutaneous Injection, Intravenous Infusion 3) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors 4) By End User: Hospitals, Oncology Clinics, Home Healthcare

What Are The Drivers Of The Phesgo Market?

The increasing incidence of breast cancer is expected to propel the growth of the phesgo market going forward. Breast cancer is a type of cancer that begins in the cells of the breast, typically in the milk ducts or lobules, and can spread to other parts of the body. The increasing incidence of breast cancer is attributed to factors such as aging populations, genetic predisposition, lifestyle changes, environmental exposures, and hormonal influences. Phesgo helps breast cancer patients by delivering a convenient, fixed-dose combination of pertuzumab and trastuzumab, two targeted therapies that work synergistically to inhibit the HER2 protein responsible for tumor growth and progression while reducing administration time and improving the overall treatment experience. For instance, according to the American Cancer Society, a US-based professional organization, the number of new breast cancer cases in the United States rose from 300,590 in 2023 to 313,510 in 2024. Therefore, the increasing incidence of breast cancer is driving the growth of the phesgo industry. The growing demand for personalized medicine is expected to propel the growth of the phesgo market going forward. Personalized medicine refers to the tailoring of medical treatment to the individual characteristics of each patient, including their genetic makeup, lifestyle, and environment, to provide more effective and targeted therapies. The growing demand for personalized medicine is attributed to advancements in genomics, enabling tailored treatments that improve outcomes and reduce side effects. Phesgo advances personalized medicine by combining pertuzumab and trastuzumab, two targeted therapies tailored to block the HER2 protein in HER2-positive breast cancer patients, into a single, subcutaneous injection that streamlines treatment delivery and aligns with individual patient needs for precision care. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, in 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of the phesgo industry.

Key Players In The Global Phesgo Market

Major companies operating in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.

Global Phesgo Market Trends and Insights

Key Companies operating in the phesgo market are focused on introducing innovative therapies such as monoclonal antibody combination therapy to enhance treatment efficacy and improve patient outcomes in oncology. Monoclonal antibody combination therapy refers to the use of two or more monoclonal antibodies together to target different aspects of a disease, often improving treatment effectiveness and overcoming potential resistance mechanisms. For instance, in November 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Phesgo combination for Subcutaneous Injection MA, IN. Phesgo is a combination injectable medication that delivers pertuzumab and trastuzumab, two monoclonal antibodies, along with hyaluronidase alfa to treat HER2-positive breast cancer and advanced HER2-positive colorectal cancer, offering a convenient subcutaneous administration alternative to intravenous infusion.

Regional Insights

North America was the largest region in the phesgo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Phesgo Market?

The phesgo market consists of sales of complementary chemotherapy agents, diagnostic and monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Phesgo Market Report 2026?

The phesgo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the phesgo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.